Is a New Immune Response Mediator in the NF-κB Pathway - SUMO-4 - Related to Type 1 Diabetes?

Review of Diabetic Studies - Germany
doi 10.1900/rds.2005.2.58
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Society for Biomedical Diabetes Research (SBDR)

Related search

MANF Inhibits Liver Cancer via SUMO Ylation‐related Suppression of NF ‐κB/Snail Signaling Pathway and Epithelial‐mesenchymal Transition

Hepatology
MedicineHepatology
2020English

Targeting the Alternative NF-κB Pathway in Pancreatic Cancer: A New Direction for Therapy?

Expert Review of Anticancer Therapy
OncologyPharmacology
2013English

MicroRNA Let-7 Modulates the Immune Response to Mycobacterium Tuberculosis Infection via Control of A20, an Inhibitor of the NF-κB Pathway

Cell Host and Microbe
ImmunologyMolecular BiologyCancer ResearchVirologyMicrobiologyMicrobiology Parasitology
2015English

Immune Intervention in Type 1 Diabetes

Diabetes Technology and Therapeutics
MedicineEndocrinologyMedical Laboratory TechnologyMetabolismDiabetes
2020English

Non-Canonical NF-κB Signaling Pathway

Cell Research
Cell BiologyMolecular Biology
2010English

Immune Receptor Signaling: From Ubiquitination to NF-κB Activation

Cellular and Molecular Immunology
Infectious DiseasesMedicineAllergyImmunology
2012English

NF-κB-related Genetic Diseases

Cell Death and Differentiation
Cell BiologyMolecular Biology
2006English

The NALP3 Inflammasome Is Required for Collagen Synthesis via the NF‑κB Pathway

International Journal of Molecular Medicine
MedicineGenetics
2018English

C-Rel Is a Critical Mediator of NF-κB-dependent TRAIL Resistance of Pancreatic Cancer Cells

Cell Death and Disease
Molecular NeuroscienceImmunologyCell BiologyCancer ResearchCellularMedicine
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy